These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31859147)

  • 1. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
    Asano Y; Varga J
    Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early inflammatory players in cutanous fibrosis.
    Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
    J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
    Korman B
    Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
    Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.
    Ntelis K; Solomou EE; Sakkas L; Liossis SN; Daoussis D
    Semin Arthritis Rheum; 2017 Dec; 47(3):409-417. PubMed ID: 28602360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging targets of disease-modifying therapy for systemic sclerosis.
    Volkmann ER; Varga J
    Nat Rev Rheumatol; 2019 Apr; 15(4):208-224. PubMed ID: 30796362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting vascular disease in systemic sclerosis.
    Kowal-Bielecka O
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting fibrosis in systemic sclerosis.
    Lafyatis R
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):395-400. PubMed ID: 17214585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
    Henry TW; Mendoza FA; Jimenez SA
    Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future targets in the management of systemic sclerosis.
    Tyndall A; Matucci-Cerinic M; Müller-Ladner U
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.